The American Society for Radiation Oncology (ASTRO), the leading organization for physicians who treat patients using radiation therapy, recently welcomed Karen Davis as its first Vice President of Business Development and Marketing. “Karen’s proven record of building high-impact partnerships and mobilizing resources for mission-driven organizations will help ASTRO accelerate initiatives that improve care for patients with cancer worldwide,” said ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO.

A new paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence of an atypical fusion gene. The case underscores the importance of molecular testing in correctly diagnosing certain cancers, said first author Shuanzeng “Sam” Wei, MD, PhD, an Associate Professor in the Department of Pathology and Medical Director of the Clinical Genomics Laboratory at Fox Chase. He said the team published their case study to raise awareness that the absence of the typical MYB/MYBL1 fusion genes does not rule out ACC and that the novel NFIB fusion gene can also be diagnostic.